![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1534411
¼¼°èÀÇ ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м®, ±âȸ ¹× ¿¹Ãø(2019-2030³â)Acute Bacterial Skin and Skin Structure Infections Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019-2030, Segmented By Type of Infection; By Route of Administration; By Distribution Channel; By Region |
¼¼°èÀÇ ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI, Acute Bacterial Skin and Skin Structure Infections) ½ÃÀå ±Ô¸ð´Â CAGR 2.4¹è·Î ±ÞÁõÇϰí 2030³â±îÁö 235¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀåÀº ABSSSIÀÇ ÀÌȯÀ² Áõ°¡, Ç×»ýÁ¦ ³»¼º, Ä¡·á ¿É¼ÇÀÇ Áøº¸, ÀÇ·áºñ Áõ°¡³ª °è¸ù Ȱµ¿ µî¿¡ ÀÇÇØ ÇöÀúÇÑ ¼ºÀå·üÀ» ±â·ÏÇÏ¸ç ¼ºÀå Çϰí ÀÖ½À´Ï´Ù.
º» º¸°í¼¿¡¼´Â 2023³â ¼¼°è ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀå ±Ô¸ð¸¦ ±Ý¾× ±âÁØÀ¸·Î 96¾ï 5,000¸¸ ´Þ·¯·Î ÃßÁ¤Çß½À´Ï´Ù. 2024-2030³â¿¡ °ÉÄ£ ¿¹Ãø±â°£ µ¿¾È ¼¼°èÀÇ ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀå ±Ô¸ð´Â CAGR 10.55%·Î È®´ëµÇ¾î 2030³â¿¡´Â 234¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î BlueWeave´Â ¿¹Ãø ÀÖ½À´Ï´Ù. ¼¼°èÀÇ ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀåÀº Á¦¾àȸ»ç¿Í ¹ÙÀÌ¿ÀÀǾàǰȸ»ç¿¡ ÀÇÇÑ ÀÎÁöµµÀÇ Çâ»ó°ú ¿¬±¸°³¹ß Ȱµ¿¿¡ ÀÇÇØ ÇöÀúÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °¨¿°À» ÀÏÀ¸Å°´Â ÀϹÝÀûÀÎ ¹ÚÅ׸®¾Æ´Â ¿¬¼â»ó±¸±Õ°ú Ȳ»öÆ÷µµ»ó±¸±ÕÀ» Æ÷ÇÔÇϸç, Ç× MRSA ¾à¹°Àº Áß¿äÇÑ ½ÅÈï °³³äÀÔ´Ï´Ù. ÆÄÀÌÇÁ¶óÀÎ °³Ã´, ¿¬±¸°³¹ßºñ, ÀǾàǰ ½ÂÀÎÀÌ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Melinta Therapeutics¿Í °°Àº ÁÖ¿ä ½ÃÀå ±â¾÷Àº ¶ÇÇÑ ¸®Æ÷±Û¸®ÄÚÆéŸÀ̵å Ç×»ýÁ¦ KIMYRSA¿Í °°Àº ½ÅÁ¦Ç° ¹× Ȱµ¿À» ½ÃÀÛÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±âȸ : Áø´Ü ¹× Ä¡·áÀÇ ±â¼ú Áøº¸
Áø´Ü µµ±¸ ¹× Ä¡·á ¹æ¹ýÀÇ ÃÖ±Ù ±â¼ú Çõ½ÅÀº ¼¼°èÀÇ ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°(ABSSSI) ½ÃÀåÀÇ »óȲÀ» º¯È½Ã۰í ÀÖ½À´Ï´Ù. ÷´Ü À̹Ì¡ ±â¼ú°ú ½Å¼ÓÇÑ Áø´Ü Å×½ºÆ®´Â Á¶±â ¹ß°ßÀ» °ÈÇÏ¿© ½Å¼ÓÇÑ °³ÀÔ°ú ȯÀÚ °á°ú¸¦ °³¼±ÇÕ´Ï´Ù. ¶ÇÇÑ Ç×»ýÁ¦ ³»¼º ±ÕÁÖ¿¡ ´ëÀÀÇÏ´Â ½Å±Ô Ç×»ýÁ¦¿Í Ä¡·á¹ýÀÇ °³¹ß·Î Áö±Ý±îÁö ÃæÁ·µÇÁö ¸øÇß´ø ÀÇ·á ¿ä±¸¿¡ ´ëÇÑ ´ëÀÀÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû Áøº¸´Â Àç¿øÀϼö³ª ÇコÄÉ¾î ºñ¿ëÀ» »è°¨ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ½ÃÀå ¹üÀ§¸¦ ¼¼°èÀûÀ¸·Î È®´ëÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ABSSSI ½ÃÀåÀº ÀÇ·á ±â¼úÀÇ ²÷ÀÓ¾ø´Â Áøº¸·Î Å©°Ô ¼ºÀåÇϴ ż¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.
ÁöÁ¤ÇÐÀû ±äÀå Áõ°¡°¡ ¼¼°èÀÇ ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
ÁöÁ¤ÇÐÀû ±äÀåÀÇ °ÝÈ´Â ¼¼°èÀÇ ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀå¿¡ Å« È¥¶õÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ƯÈ÷ Ç×»ýÁ¦ ¹× ÀÇ·á¿ëǰ °ø±Þ¸ÁÀÇ È¥¶õÀº ȯÀÚÀÇ Ä¡·á¿Í Ä¡·á È¿°ú¸¦ ¹æÇØÇÕ´Ï´Ù. Á¤Á¤ ºÒ¾È°ú °æÁ¦ Á¦Àçµµ ÀǾàǰÀÇ Á¦Á¶¿Í À¯Åë¿¡ ÁöÀåÀ» ÃÊ·¡ÇÏ¿© ÀǾàǰ ºÎÁ·°ú ºñ¿ë Áõ°¡·Î À̾îÁý´Ï´Ù. ±¹Á¦ÀûÀÎ Çù·Â°ü°èÀÇ ÀúÇÏ¿Í ¿Ü±³°ü°èÀÇ ±äÀåÀº ¿¬±¸°³¹ßÀÇ ³ë·ÂÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀå
±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀå : À¯Åë ä³Îº°
À¯Åë ä³Îº°·Î º¸¸é, ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀåÀº º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹ÀÇ °¢ ºÎ¹®À¸·Î ³ª´¹´Ï´Ù. º´¿ø ¾à±¹ ºÎ¹®Àº º¹ÀâÇÑ °¨¿°À» È¿°úÀûÀ¸·Î °ü¸®Çϰí, ÇÊ¿äÇÑ ¾à¹°À» Àû½Ã¿¡ Á¦°øÇϰí, ƯÈ÷ Áï°¢ÀûÀ̰í ÁýÁßÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÑ º´¿ø ȯ°æ¿¡¼ °í±Þ °Ç° °ü¸® ÀÎÇÁ¶ó¸¦ Á¦°øÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ ¼¼°èÀÇ ABSSSI ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.
°æÀï ±¸µµ
¼¼°èÀÇ ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀåÀº °æÀïÀÌ ½ÉÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Pfizer, Merck&Co., AbbVie, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson&Johnson, Eli Lilly and Company, Novartis AG, Sanofi SA, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, and Mylan NV¸¦ µé ¼ö ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº ¼¼°èÀÇ ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀå¿¡¼ ÁöÀ§¸¦ ´õ¿í °ÈÇϱâ À§ÇØ ¿¬±¸°³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ÇÕº´¡¤Àμö, ÇÕÀÛ»ç¾÷, Á¦ÈÞ, ¶óÀ̼±½º °è¾à, ½ÅÁ¦Ç°¡¤¿ë·® Ãâ½Ã µî, ´Ù¾çÇÑ Àü·«À» ±¸»çÇϰí ÀÖ½À´Ï´Ù.
»ó¼¼ÇÑ ºÐ¼®Àº ¼¼°è ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°(ABSSSI) ½ÃÀåÀÇ ¼ºÀå °¡´É¼º, ¹Ì·¡ µ¿Çâ ¹× Åë°è¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÃÑ ½ÃÀå ±Ô¸ð ¿¹ÃøÀ» ÃËÁøÇÏ´Â ¿äÀο¡µµ ÁÖ¸ñÇϰí ÀÖ½À´Ï´Ù. ¼¼°èÀÇ ±Þ¼º ¼¼±Õ¼º ÇǺΠ¹× ÇǺΠ±¸Á¶ °¨¿°Áõ(ABSSSI) ½ÃÀåÀÇ Ãֽбâ¼ú µ¿Çâ°ú ÀÇ»ç °áÁ¤ÀÚ°¡ °ÇÀüÇÑ Àü·«Àû ÀÇ»ç °áÁ¤À» ½Ç½ÃÇϱâ À§ÇÑ »ê¾÷ ÀλçÀÌÆ®ÀÇ Á¦°øÀ» ¾à¼ÓÇÕ´Ï´Ù. ¶ÇÇÑ ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀΡ¤°úÁ¦¡¤°æÀï·Â¿¡ ´ëÇØ¼µµ ºÐ¼®Çß½À´Ï´Ù.
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Size Zooming 2.4X at Stellar CAGR to Touch USD 23.5 Billion by 2030
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is flourishing at a significant growth rate due to increasing ABSSSI incidence rates, antibiotic resistance, advancements in treatment options, and rising healthcare expenditure and awareness initiatives.
BlueWeave Consulting, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market size by value at USD 9.65 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market size to expand at a CAGR of 10.55% reaching a value of USD 23.49 billion in 2030. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is growing at a significant rate due to increasing awareness and R&D activities by pharmaceutical and biopharmaceutical companies. Common bacteria causing these infections include Streptococcus pyogenes and Staphylococcus aureus, with anti-MRSA drugs being a crucial emerging concept. Pipeline development, R&D expenditure, and drug approvals are expected to drive the market. Key market players, such as Melinta Therapeutics, are also launching new products and activities, such as KIMYRSA, a lipoglycopeptide antibiotic. These factors are expected to drive the market during the forecast period.
Opportunity - Technological advancements in diagnostics and treatment
Recent innovations in diagnostic tools and treatment modalities are revolutionizing the landscape of Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market. Advanced imaging techniques and rapid diagnostic tests are enhancing early detection, leading to prompt interventions and improved patient outcomes. Moreover, the development of novel antibiotics and therapies tailored to antibiotic-resistant strains is addressing previously unmet medical needs. These technological strides are not only reducing hospital stays and healthcare costs but also expanding the market scope globally. As a result, Global ABSSSI Market is poised for substantial growth driven by continuous advancements in medical technology.
Impact of Escalating Geopolitical Tensions on Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
Intensifying geopolitical tensions are causing significant disruptions in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market. Disruptions in supply chains, particularly for antibiotics and medical supplies, hinder patient care and treatment efficacy. Political instability and economic sanctions can also hinder pharmaceutical manufacturing and distribution, leading to drug shortages and increased costs. Reduced international collaboration and strained diplomatic relations can stifle research and development efforts.
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - By Distribution Channel
Based on distribution channel, Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The hospital pharmacies segment dominates the Global ABSSSI Market due to their ability to manage complex infections effectively, provide timely access to necessary medications, and offer advanced healthcare infrastructure, particularly in hospital settings where immediate and intensive care is required.
Competitive Landscape
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is fiercely competitive. Major companies in the market include Pfizer, Merck & Co., AbbVie, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson & Johnson, Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, and Mylan N.V. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and dose releases to further strengthen their position in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable